Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

EXODIAB/LUDC-IRC: A powerhouse for diabetes research

What are the challenges within diabetes research today? And what are the strenghts of Lund university Diabetes Centre (LUDC) to meet those challenges?

A powerhouse for diabetes research
A powerhouse for diabetes research

- Diabetes today is one of the largest global health problems that we have. I think that one of the main challenges we have is to make sure that we consider the patient and make sure we have proper therapies to offer, says Maria Gomez, coordinator LUDC-IRC.

Flemming Pociot, Steno Diabetes Centre and member of the scientific advisory board of LUDC-IRC:

- I think one of the major challenges is that we are now recognizing that diabetes is a much more heterogenous disease than we previously anticipated, we have to be much better in phenotyping our patients to treat them the right way. This is one way to aim to a more personalized approach to taking care of our patients. That is a major challenge and I think you are actually world leading in this aspect.

Julia Brosnan, Pfizer and member of the scientific advisory board of LUDC-IRC:

- I think it is really important industry and academia keep talking to each other, we approach drug discovery in different ways that academia looks at the mechanistic ways and industry is trying to apply its problems, and really to do this effectively we need to work togheter why it is important we be here and talk to the investigators is so chritical. As we talk together we learn what the common interest are and how we apply the new biology to the new drug program and drug target we are working on within the industry.

- I think LUDC is a powerhouse for approaching these questions. You have a fantastic research environment and a strong tradition, going from molecule to the bedside to the patient. The setting is very good; you have basic science, you can take care of patients on the same campus, you can very easily translate what you observe in research into that clinical setting, which I think is a good strength of LUDC, Flemming Pociot continues.

- It is a very stimulating environment, we have access to incredible patient cohorts and observational studies and we have gathered al lot of data already and will generate even more data and we have the competence and expertise to interrogate that data in an efficiant way, Maria Gomez concludes.

Text and video: Sara Liedholm